NEUROTECH INTERNATIONAL ORD
Neurotech International Secures HREC Approval for Pivotal Phase 3 ASD Study of NTI164
Neurotech International (ASX: NTI) has secured Human Research Ethics Committee (HREC) approval to commence its pivotal Phase 3 clinical study for **NTI16
Neurotech International admits final patient for NTI164 Phase II/III trial to treat autism
Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has confirmed that the last patient in a Phase II/III NTIASD2 clinical trial for children with autism spectrum disorder (ASD) has completed their final visit. The child was the 54th patient to take part in the trial, which recruited individuals between the ages of 8 and 17 […]
Australian biotech sector tipped for strong growth
Recent studies have highlighted the significant potential the Australian biotech industry has ahead of it. International research firm KPMG recently forecast Australia could generate over $15 billion in exports to the United States and create 34,000 high-skilled jobs by accelerating US-Australia biotechnology collaboration. Australia’s $1.2b biotech industry currently ranks fifth in the world in terms […]
Neurotech International extends NTI164 Rett Syndrome trial to 52 weeks
Biopharmaceutical development company Neurotech International (ASX: NTI) has extended a Phase I/II clinical trial investigating the use of NTI164 in female Rett Syndrome patients to 52 weeks. The extension replaces the previous 16-week duration and was approved by the human research ethics committee at Sydney’s Children’s Hospital at Westmead under clinical trial protocol. A total […]